Inventor · disambiguated record
James Sheppeck
Also filed as: SHEPPECK JAMES · SHEPPECK JAMES E · SHEPPECK JAMES EDWARD
28 granted patents·13 pending applications·186 citations·filing 2001–2025
96Inventor score
Files withBRISTOL MYERS SQUIBB CO12CYCLERION THERAPEUTICS INC12IRONWOOD PHARMACEUTICALS INC7ASTRAZENECA AB3BRISTOL MYERS SQUIBB PHARMA CO3
Top patents by PatentIndex Score
41 records- 0194US9586937B2sGC stimulatorsIRONWOOD PHARMACEUTICALS INC·Filed 2016·Granted Mar 7, 2017·13 cites·2 claims
- 0293US9481689B2sGC stimulatorsIRONWOOD PHARMACEUTICALS INC·Filed 2014·Granted Nov 1, 2016·16 cites·2 claims
- 0391US10183021B2sGC stimulatorsIRONWOOD PHARMACEUTICALS INC·Filed 2016·Granted Jan 22, 2019·8 cites·9 claims
- 0490US10639308B2sGC stimulatorsCYCLERION THERAPEUTICS INC·Filed 2018·Granted May 5, 2020·3 cites·31 claims
- 0590US6906053B2Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE)BRISTOL MYERS SQUIBB PHARMA CO·Filed 2004·Granted Jun 14, 2005·33 cites·24 claims
- 0690US6890915B2Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE)BRISTOL MYERS SQUIBB PHARMA CO·Filed 2002·Granted May 10, 2005·32 cites·24 claims
- 0789US7041693B2Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE)BRISTOL MYERS SQUIBB CO·Filed 2003·Granted May 9, 2006·26 cites·18 claims
- 0889US2025243228A1PHOSPHORUS PRODRUGS OF PYRAZOLO-SUBSTITUTED PYRIMIDINE sGC STIMULATORSCYCLERION THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0987US10517874B2sGC stimulatorsCYCLERION THERAPEUTICS INC·Filed 2017·Granted Dec 31, 2019·4 cites·17 claims
- 1086US2024360164A1Phosphorus prodrugs of pyrazolo-substituted pyrimidine sgc stimulatorsCYCLERION THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1185US2024228520A9Phosphorus prodrugs of pyrazolo-substituted pyrimidine sgc stimulatorsCYCLERION THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1284US7253283B2Tricyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereofBRISTOL MYERS SQUIBB CO·Filed 2005·Granted Aug 7, 2007·6 cites·15 claims
- 1383US8399451B2Heterocyclic compoundsGILMORE JOHN L·Filed 2010·Granted Mar 19, 2013·12 cites·11 claims
- 1481US7482372B2Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE)BRISTOL MYERS SQUIBB CO·Filed 2005·Granted Jan 27, 2009·4 cites·6 claims
- 1577US10844064B2sGC stimulatorsCYCLERION THERAPEUTICS INC·Filed 2015·Granted Nov 24, 2020·2 cites·9 claims
- 1677US2023106002A1sGC STIMULATORSCYCLERION THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1776US7211671B2Substituted 1,3-dihydro-imidazol-2-one and 1,3-dihydro-imidazol-2-thione derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE)BRISTOL MYERS SQUIBB CO·Filed 2004·Granted May 1, 2007·15 cites·12 claims
- 1873US7074810B2Triazolone and triazolethione derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzymeBRISTOL MYERS SQUIBB CO·Filed 2003·Granted Jul 11, 2006·6 cites·23 claims
- 1971US11207323B2sGC stimulatorsCYCLERION THERAPEUTICS INC·Filed 2020·Granted Dec 28, 2021·0 cites·4 claims
- 2070US8067447B2Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereofSHEPPECK JAMES E·Filed 2007·Granted Nov 29, 2011·2 cites·12 claims
- 2170US2021221793A1Pyrazole derivatives as sgc stimulatorsCYCLERION THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2269US6770647B2Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE)BRISTOL MYERS SQUIBB PHARMA CO·Filed 2002·Granted Aug 3, 2004·4 cites·15 claims
- 2368US2024247001A12,6,9-trisubstituted purinesASTRAZENECA AB·Filed 2023·Application pending·0 cites
- 2467US10927136B2Phosphorus prodrugs of pyrazolo-substituted pyrimidine sGC stimulatorsCYCLERION THERAPEUTICS INC·Filed 2017·Granted Feb 23, 2021·0 cites·16 claims
- 2564US12441744B22,6,9-trisubstituted purinesASTRAZENECA AB·Filed 2025·Granted Oct 14, 2025·0 cites·19 claims
- 2661US2021214364A1sGC STIMULATORSCYCLERION THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2760US2019284168A1Pyrazole derivaties as sgc stimulatorsIRONWOOD PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 2858US2019031641A1Pyrazole derivatives as sgc stimulatorsIRONWOOD PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 2957US2024374606A1Substituted pyrazine-2-carboxamides as hpk1 inhibitors for the treatment of cancerASTRAZENECA AB·Filed 2022·Application pending·0 cites
- 3056US7544808B2Tricyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereofBRISTOL MYERS SQUIBB CO·Filed 2007·Granted Jun 9, 2009·0 cites·14 claims
- 3153US2016311826A1Sgc stimulatorsIRONWOOD PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 3251US2017291889A1Pyrazole derivatives as sgc stimulatorsIRONWOOD PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 3348US7994190B2Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereofBRISTOL MYERS SQUIBB CO·Filed 2007·Granted Aug 9, 2011·0 cites·14 claims
- 3447US11357777B2Use of sGC stimulators for the treatment of nonalcoholic steatohepatitis (NASH)CYCLERION THERAPEUTICS INC·Filed 2017·Granted Jun 14, 2022·0 cites·23 claims
- 3546US2002058788A1Facile deprotection of Fmoc protected amino groupsFiled 2001·Application pending·0 cites
- 3645US7625921B2Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereofBRISTOL MYERS SQUIBB CO·Filed 2005·Granted Dec 1, 2009·0 cites·14 claims
- 3745US7605264B2Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereofBRISTOL MYERS SQUIBB CO·Filed 2005·Granted Oct 20, 2009·0 cites·15 claims
- 3845US7569689B2Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereofBRISTOL MYERS SQUIBB CO·Filed 2005·Granted Aug 4, 2009·0 cites·15 claims
- 3945US7132432B2Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE)BRISTOL MYERS SQUIBB CO·Filed 2004·Granted Nov 7, 2006·0 cites·15 claims
- 4044US8198311B2Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereofSHEPPECK JAMES E·Filed 2007·Granted Jun 12, 2012·0 cites·9 claims
- 4143US7361654B2Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereofBRISTOL MYERS SQUIBB CO·Filed 2006·Granted Apr 22, 2008·0 cites·14 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →